Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 1
1963 6
1964 4
1965 4
1966 8
1967 2
1968 4
1969 6
1970 3
1971 9
1972 6
1973 5
1974 4
1975 1
1976 3
1978 5
1979 5
1980 4
1981 6
1982 3
1983 1
1984 3
1985 5
1986 8
1987 7
1988 5
1989 10
1990 19
1991 19
1992 15
1993 13
1994 12
1995 25
1996 27
1997 9
1998 25
1999 25
2000 18
2001 26
2002 34
2003 31
2004 28
2005 34
2006 46
2007 44
2008 52
2009 46
2010 39
2011 52
2012 50
2013 68
2014 75
2015 64
2016 65
2017 66
2018 58
2019 65
2020 33
Text availability
Article attribute
Article type
Publication date

Search Results

1,193 results
Results by year
Filters applied: . Clear all
Page 1
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K. Takegawa N, et al. Among authors: Kawakami H. Int J Cancer. 2019 Dec 15;145(12):3414-3424. doi: 10.1002/ijc.32408. Epub 2019 May 24. Int J Cancer. 2019. PMID: 31087550
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K. Kawakami H, et al. Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20. Invest New Drugs. 2017. PMID: 28317087
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K. Shimizu T, et al. Among authors: Kawakami H. Invest New Drugs. 2016 Jun;34(3):347-54. doi: 10.1007/s10637-016-0347-6. Epub 2016 Mar 22. Invest New Drugs. 2016. PMID: 27000274 Free PMC article. Clinical Trial.
Clinical and immune profiling for cancer of unknown primary site.
Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, Chiba Y, Sawada T, Sakai K, Fujita Y, Togashi Y, Tanizaki J, Kawakami H, Ito A, Nishio K, Nakagawa K. Haratani K, et al. Among authors: Kawakami H. J Immunother Cancer. 2019 Sep 13;7(1):251. doi: 10.1186/s40425-019-0720-z. J Immunother Cancer. 2019. PMID: 31519206 Free PMC article.
An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K. Yonesaka K, et al. Among authors: Kawakami H. Oncogene. 2019 Feb;38(9):1398-1409. doi: 10.1038/s41388-018-0517-4. Epub 2018 Oct 9. Oncogene. 2019. PMID: 30302022
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Muro K, et al. Among authors: Kawakami H. Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502. Ann Oncol. 2019. PMID: 30475956 Free article.
IgG4-related sclerosing cholangitis: all we need to know.
Zen Y, Kawakami H, Kim JH. Zen Y, et al. Among authors: Kawakami H. J Gastroenterol. 2016 Apr;51(4):295-312. doi: 10.1007/s00535-016-1163-7. Epub 2016 Jan 27. J Gastroenterol. 2016. PMID: 26817943 Review.
1,193 results
Jump to page
Feedback